{
  "id": 4791501,
  "title": "Pharmaindustrie: Novartis stoppt nach Todesfällen Studien zu Zelltherapie",
  "url": "https://urgent.news/2026/09/01/pharmaindustrie-novartis-stoppt-nach-todesfallen-studien-zu",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-01T05:02:17.000Z",
  "source": {
    "name": "Handelsblatt",
    "slug": "handelsblatt",
    "url": "https://www.handelsblatt.com/technik/medizin/pharmaindustrie-novartis-stoppt-nach-todesfaellen-studien-zu-zelltherapie/100251018.html"
  },
  "original_language": "de",
  "account": "Swiss pharmaceutical giant Novartis has suspended several clinical trials for an experimental therapy following the deaths of three patients, according to a media report. The Wall Street Journal reported on Tuesday, citing a company spokesperson, that eight studies on treatments for autoimmune and neurological illnesses were halted in late August. The cause of these three fatal cases of severe immune reaction is unclear. Novartis is conducting a thorough review of the incidents, the spokesperson told the newspaper. Such immune reaction is a known risk for the so-called CAR-T-cell therapy. The company is working with independent safety boards and shares its findings with regulatory authorities. CAR-T therapies involve altering a patient's immune cells so they can recognize and destroy cancer cells. US corporation Bristol-Myers Squibb also paused similar CAR-T trials for autoimmune diseases as a precautionary measure, the paper added. Novartis and Bristol-Myers Squibb were initially unavailable for comment to Reuters.",
  "summary": "Mit einer Zelltherapie wollte der Konzern Autoimmunerkrankungen behandeln. Doch bei klinischen Studien soll es zu Todesfällen gekommen sein. Darum wird die Entwicklung vorerst gestoppt.",
  "key_points": [
    "Novartis suspends 8 CAR-T cell therapy studies post 3 patient deaths",
    "Cause of fatal immune reactions unclear, company reviews incidents",
    "Bristol-Myers Squibb pauses similar CAR-T trials as precaution"
  ],
  "editors_take": "The suspension of Novartis' CAR-T-cell therapy trials highlights the risks associated with this treatment, putting its potential to treat autoimmune and neurological illnesses in question.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}